Eli Lilly and Company (NYSE:LLY) Shares Sold by Swiss National Bank

Swiss National Bank decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,523,290 shares of the company’s stock after selling 72,000 shares during the quarter. Eli Lilly and Company comprises about 1.1% of Swiss National Bank’s investment portfolio, making the stock its 11th largest holding. Swiss National Bank’s holdings in Eli Lilly and Company were worth $1,470,876,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of LLY. Fisher Asset Management LLC lifted its position in Eli Lilly and Company by 2.0% in the 4th quarter. Fisher Asset Management LLC now owns 4,544,585 shares of the company’s stock valued at $2,649,130,000 after purchasing an additional 87,511 shares during the last quarter. LGT Fund Management Co Ltd. grew its position in Eli Lilly and Company by 4.4% in the 4th quarter. LGT Fund Management Co Ltd. now owns 9,520 shares of the company’s stock worth $5,530,000 after purchasing an additional 400 shares during the last quarter. Heritage Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $1,298,000. Robertson Stephens Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 30.6% during the fourth quarter. Robertson Stephens Wealth Management LLC now owns 4,145 shares of the company’s stock valued at $2,416,000 after buying an additional 971 shares during the last quarter. Finally, McIlrath & Eck LLC raised its holdings in shares of Eli Lilly and Company by 16.5% during the fourth quarter. McIlrath & Eck LLC now owns 465 shares of the company’s stock valued at $271,000 after buying an additional 66 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on LLY. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research report on Wednesday, February 21st. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup increased their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, Barclays raised their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $18.26 on Thursday, reaching $758.49. 1,584,206 shares of the company traded hands, compared to its average volume of 3,049,690. The stock has a market capitalization of $720.69 billion, a PE ratio of 111.71, a P/E/G ratio of 1.58 and a beta of 0.37. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company’s 50 day moving average is $762.03 and its 200-day moving average is $669.96. Eli Lilly and Company has a fifty-two week low of $414.31 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 59.28% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the firm earned $1.62 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, analysts anticipate that Eli Lilly and Company will post 13.5 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.